131 related articles for article (PubMed ID: 20671559)
1. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature.
Correia LM; Bonilha DQ; Ramos JD; Ambrogini O; Miszputen SJ
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1260-4. PubMed ID: 20671559
[TBL] [Abstract][Full Text] [Related]
2. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
[No Abstract] [Full Text] [Related]
3. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
4. Infliximab treatment and pregnancy outcome in active Crohn's disease.
Srinivasan R
Am J Gastroenterol; 2001 Jul; 96(7):2274-5. PubMed ID: 11467677
[No Abstract] [Full Text] [Related]
5. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
6. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Kopylov U; Mantzaris GJ; Katsanos KH; Reenaers C; Ellul P; Rahier JF; Israeli E; Lakatos PL; Fiorino G; Cesarini M; Tsianos EV; Louis E; Ben-Horin S
Aliment Pharmacol Ther; 2011 Feb; 33(3):349-57. PubMed ID: 21118397
[TBL] [Abstract][Full Text] [Related]
8. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
Katz JA; Antoni C; Keenan GF; Smith DE; Jacobs SJ; Lichtenstein GR
Am J Gastroenterol; 2004 Dec; 99(12):2385-92. PubMed ID: 15571587
[TBL] [Abstract][Full Text] [Related]
9. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
10. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment for symptomatic Crohn's disease strictures.
Pelletier AL; Kalisazan B; Wienckiewicz J; Bouarioua N; Soulé JC
Aliment Pharmacol Ther; 2009 Feb; 29(3):279-85. PubMed ID: 19035967
[TBL] [Abstract][Full Text] [Related]
12. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance.
Francis G; Duggan A
Gastroenterology; 2008 Dec; 135(6):2156-7. PubMed ID: 19013168
[No Abstract] [Full Text] [Related]
13. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
Kane S; Ford J; Cohen R; Wagner C
J Clin Gastroenterol; 2009 Aug; 43(7):613-6. PubMed ID: 19142167
[TBL] [Abstract][Full Text] [Related]
14. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
Gisbert JP; Panés J
Am J Gastroenterol; 2009 Mar; 104(3):760-7. PubMed ID: 19174781
[TBL] [Abstract][Full Text] [Related]
15. [Optimizing effect of infliximab upon inflammatory bowel disease].
Li SR; Sheng JQ; Li SJ; Zhao XJ
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
[TBL] [Abstract][Full Text] [Related]
16. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
17. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
18. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
19. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients.
Pedersen N; Duricova D; Lenicek M; Elkjaer M; Bortlik M; Andersen PS; Vitek L; Davidsen B; Wewer V; Lukas M; Munkholm P
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1196-203. PubMed ID: 20739896
[TBL] [Abstract][Full Text] [Related]
20. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
